Abstract：
UNASSIGNED: Many people with cystic fibrosis (PwCF) have chronic rhinosinusitis (CRS). CRS requires additional management beyond that of pulmonary disease and leads to increased utilization of healthcare resources. Elexacaftor/tezacaftor/ivacaftor (ETI) is a highly effective modulator therapy that has been shown to improve CRS in PwCF. However, the impact of ETI on rhinologic healthcare utilization is understudied.
UNASSIGNED: To compare rates of rhinologic healthcare utilization and procedures among PwCF prior to and after initiating ETI therapy.
UNASSIGNED: A single-center, cohort study investigating adult PwCF was performed in January 2023. Demographics, clinical characteristics, and data related to CF treatment were retrospectively abstracted. Characteristics of the cohort were compared over 2 periods: the 12-months prior to ETI initiation and the 12-months after ETI initiation. Post-ETI data were linearly extrapolated if a subject had not yet completed the full 12 months of ETI. Paired t-testing, Wilcoxon signed rank testing, and regression analysis were performed.
UNASSIGNED: Of 126 PwCF, 98 (77.8%) were on ETI therapy and 35 (27.7%) were both on ETI and concurrently followed by the rhinology service (ETI-ENT). Rhinology clinic visits (P = .007) and frequency of obtaining nasal cultures (P = .046) decreased for the ETI-ENT cohort after initiating ETI treatment. There were no significant changes in the number of endoscopic sinus surgeries (P = .452) performed. Beyond ETI use, regression analysis did not identify any factors associated with changes in utilization.
UNASSIGNED: Aspects of rhinology healthcare utilization by PwCF decreased after initiation of ETI therapy. Additional studies are needed to determine rhinologic healthcare requirements for PwCF who remain on ETI for the long-term and to evaluate larger cohorts of PwCF on ETI.
UNASSIGNED: To compare rates of rhinologic healthcare utilization and procedures among PwCF prior to and after initiating ETI therapy.
UNASSIGNED: A single-center, cohort study investigating adult PwCF was performed in January 2023. Demographics, clinical characteristics, and data related to CF treatment were retrospectively abstracted. Characteristics of the cohort were compared over 2 periods: the 12-months prior to ETI initiation and the 12-months after ETI initiation. Post-ETI data were linearly extrapolated if a subject had not yet completed the full 12 months of ETI. Paired t-testing, Wilcoxon signed rank testing, and regression analysis were performed.
UNASSIGNED: Of 126 PwCF, 98 (77.8%) were on ETI therapy and 35 (27.7%) were both on ETI and concurrently followed by the rhinology service (ETI-ENT). Rhinology clinic visits (P = .007) and frequency of obtaining nasal cultures (P = .046) decreased for the ETI-ENT cohort after initiating ETI treatment. There were no significant changes in the number of endoscopic sinus surgeries (P = .452) performed. Beyond ETI use, regression analysis did not identify any factors associated with changes in utilization.
UNASSIGNED: Aspects of rhinology healthcare utilization by PwCF decreased after initiation of ETI therapy. Additional studies are needed to determine rhinologic healthcare requirements for PwCF who remain on ETI for the long-term and to evaluate larger cohorts of PwCF on ETI.
摘要：
■许多患有囊性纤维化（PwCF）的人患有慢性鼻-鼻窦炎（CRS）。CRS需要除肺部疾病以外的额外管理，并导致医疗保健资源的利用增加。Elexacaftor/tezacaftor/ivacaftor（ETI）是一种高效的调节剂疗法，已被证明可改善PwCF中的CRS。然而,ETI对鼻保健利用的影响研究不足.
■比较开始ETI治疗之前和之后PwCF的鼻科医疗利用率和程序。
■单中心，调查成人PwCF的队列研究于2023年1月进行.人口统计,临床特征,并对CF治疗相关数据进行回顾性摘录.在两个时期比较了队列的特征：ETI开始前12个月和ETI开始后12个月。如果受试者尚未完成完整的12个月的ETI,则线性外推ETI后数据。配对t检验，Wilcoxon符号等级测试,并进行回归分析。
■在126个PwCF中，98例（77.8％）接受ETI治疗，35例（27.7％）均接受ETI治疗，并同时接受鼻学服务（ETI-ENT）。开始ETI治疗后，ETI-ENT队列的鼻科临床就诊（P=.007）和获得鼻培养物的频率（P=.046）降低。进行的内窥镜鼻窦手术的数量没有显着变化（P=0.452）。除了使用ETI之外，回归分析未发现任何与利用率变化相关的因素.
■开始ETI治疗后，PwCF的鼻学医疗保健利用方面下降。需要进一步的研究来确定长期使用ETI的PwCF的鼻科医疗要求，并评估更大的PwCF对ETI的队列。
■比较开始ETI治疗之前和之后PwCF的鼻科医疗利用率和程序。
■单中心，调查成人PwCF的队列研究于2023年1月进行.人口统计,临床特征,并对CF治疗相关数据进行回顾性摘录.在两个时期比较了队列的特征：ETI开始前12个月和ETI开始后12个月。如果受试者尚未完成完整的12个月的ETI,则线性外推ETI后数据。配对t检验，Wilcoxon符号等级测试,并进行回归分析。
■在126个PwCF中，98例（77.8％）接受ETI治疗，35例（27.7％）均接受ETI治疗，并同时接受鼻学服务（ETI-ENT）。开始ETI治疗后，ETI-ENT队列的鼻科临床就诊（P=.007）和获得鼻培养物的频率（P=.046）降低。进行的内窥镜鼻窦手术的数量没有显着变化（P=0.452）。除了使用ETI之外，回归分析未发现任何与利用率变化相关的因素.
■开始ETI治疗后，PwCF的鼻学医疗保健利用方面下降。需要进一步的研究来确定长期使用ETI的PwCF的鼻科医疗要求，并评估更大的PwCF对ETI的队列。
